ADC Therapeutics stops development of ADCT-602 and unveils latest Zynlonta data

ADC Therapeutics has halted development of its clinical asset ADCT-602, which was in a Phase I/II trial for relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). This leaves ADCT-701, in Phase I trials for neuroendocrine tumors, as the company’s sole clinical asset. ADC also continues preclinical development of other candidates.

Separately, ADC announced positive Phase Ib LOTIS-7 data for its main therapy, Zynlonta (loncastuximab tesirine-lpyl), combined with Roche’s Columvi (glofitamab). Among 22 patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), the combination achieved a 95.5% overall response rate and 90.9% complete response rate, with median duration of response not reached.

Zynlonta was FDA-approved in 2021 via accelerated approval and has conditional EU marketing authorization. The company recently completed the confirmatory Phase III LOTIS-5 trial and will present updated safety and efficacy data at upcoming hematology conferences.

18-05-2025